March 2026
MDMA
What March 2026's 17 new studies found, synthesized from the papers below. All MDMA research →
The synthesis
Synthesized from 17 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, then ranked by relevance.
Research on MDMA in March 2026 confirms that MDMA-assisted therapy reduces PTSD symptoms (moderate-to-large effect sizes) and increases response/remission rates, but the evidence is rated low certainty due to blinding challenges, expectancy effects, and high risk of bias. Preclinical studies show MDMA enhances fear extinction via prefrontal plasticity and reduces stress-induced alcohol intake in a genotype-dependent manner, while also revealing transient next-day anxiety and serotonin reductions in rats. A key caveat is that no new large-scale, well-controlled human trials were published in this period, and the FDA declined approval in 2024 citing insufficient evidence.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD 2026 | systematic review and meta-analysis | 286 | Supports | MDMA-assisted therapy showed greater reduction in PTSD symptoms (Hedges' g = -0.71) and higher response (RR=1.35) and remission (RR=2.25) rates compared to control, but evidence was rated low certainty by GRADE. |
| MDMA alters fear extinction, and reduces alcohol consumption in inbred alcohol preferring iP rats but not outbred Wistar rats. 2026 | preclinical (rat model) | Mixed | MDMA acutely reduced freezing during extinction but had no lasting effect on drug-free recall; it prevented shock-related increase in alcohol consumption only in iP rats, suggesting genotype-dependent effects. | |
| State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder 2026 | review | Supports | MDMA-AT shows promising outcomes in RCTs with high response/remission rates, but key limitations include blinding challenges, lack of active comparators, inadequate safety monitoring, and limited generalizability. | |
| Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes 2026 | systematic review and meta-analysis | 298 | Supports | MDMA-AT was associated with reductions in PTSD symptom severity (SMD=-1.19) and dissociative symptoms (SMD=-0.37), but most studies had high risk of bias and overall certainty was low. |
| MDMA enhances prefrontal plasticity and representational drift during fear extinction 2026 | preclinical (mouse model) | Supports | MDMA increased spine density and spinogenesis in prefrontal cortex, accelerated representational drift, and strengthened infralimbic cortex correlation with freezing suppression, suggesting enhanced neuroplasticity underlying extinction learning. | |
| A repeated low-dose regimen of MDMA has transient next-day effects on locomotor activity, anxiety-like behavior, and brain serotonin levels, with no effect on anhedonia-like behavior, in both female and male rats 2026 | preclinical (rat model) | Mixed | Repeated low-dose MDMA caused transient next-day anxiety-like behavior and reduced serotonin in nucleus accumbens, but no effect on anhedonia-like behavior; effects resolved by day 15. | |
| Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review 2026 | systematic review | Supports | MDMA and ketamine IV have the greatest support for efficacy in PTSD, but caution is needed due to treatment expectancy effects and potential for inadequate blinding. | |
| The renaissance of research on psychedelics in child and adolescent psychopharmacology 2026 | review | Unclear | Psychedelic research in pediatric populations is emerging but requires caution due to developmental vulnerabilities; MDMA is not yet studied in adolescents. | |
| Case Report: Amplified psychoanalysis? Psychoanalysis, OCD and MDMA in a clinical case study 2026 | case report | 1 | Supports | Integration of MDMA with psychoanalysis appeared to facilitate access to unconscious material and therapeutic progress in a single OCD case, but efficacy requires systematic investigation. |
| Balancing Innovation and Evidence: Reflections on Structured Protocols in MDMA-Assisted Therapy Versus a Principle-Guided, Patient-Directed Approach 2026 | theoretical/perspective | Unclear | The paper argues that embedding MDMA in structured cognitive-behavioral protocols may blunt its transformative effects and that the patient-directed model should be preserved and refined. | |
| MDMA-assisted psychotherapy in major depression: critical considerations for clinical translation: commentary, Kvam et al. 2026 | commentary | Unclear | Commentary on critical considerations for clinical translation of MDMA-assisted psychotherapy in major depression. | |
| HPLC-MS/MS stereoselective determination and quantification of MDMA and its phase-1 metabolite in human oral fluid samples: estimation of consumption time. 2026 | observational (pharmacokinetic) | 161 | Unclear | Stereoselective analysis of MDMA and MDA in oral fluid showed faster elimination of S-(+)-MDMA (half-life 3.3h) vs R-(-)-MDMA (4.8h), enabling estimation of time since ingestion. |
| Bioactivation and Metabolism of Amino Acid MDMA Prodrugs in Zebrafish Embryos, Human Liver S9, Whole Blood, and Microdosed Human Urine 2026 | preclinical (zebrafish, human liver S9, human urine) | Unclear | Amino acid prodrugs of MDMA (MDMA-Trp, MDMA-Lys, MDMA-Gly) are cleaved to MDMA in zebrafish, liver S9, and human urine, with unique biomarkers for MDMA-Trp; no cleavage in blood. | |
| Corrigendum "Withania somnifera influences MDMA-induced hyperthermic, cognitive, neurotoxic and neuroinflammatory effects in mice." [Biomed. Pharmacother. 161 (2023) 114475]. 2026 | corrigendum | Unclear | Corrigendum to a previous study on Withania somnifera influencing MDMA-induced effects in mice; no new findings. | |
| Correction to "Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights". 2026 | correction | Unclear | Correction to a study on next-generation MDMA analogue SDMA; all results and conclusions remain accurate. | |
| Exploring the Utility and Appropriateness of Dose Thresholds for Issuing of Public Drug Alerts on High-Dose MDMA: A Qualitative Study. 2026 | qualitative | 15 | Unclear | Experts agreed that 150 mg free-base MDMA is a reasonable threshold for issuing public drug alerts, though thresholds cannot account for evolving trends. |
| Eutylone history selectively impacts the rewarding and aversive effects of cocaine, MDMA, and eutylone in female Sprague-Dawley rats. 2026 | preclinical (rat model) | Mixed | History with eutylone attenuated eutylone-induced taste avoidance but did not affect MDMA- or cocaine-induced avoidance; eutylone history increased cocaine place preference but not MDMA's. |
MDMA-assisted therapy showed greater reduction in PTSD symptoms (Hedges' g = -0.71) and higher response (RR=1.35) and remission (RR=2.25) rates compared to control, but evidence was rated low certainty by GRADE.
systematic review and meta-analysis Sample size: 286
MDMA acutely reduced freezing during extinction but had no lasting effect on drug-free recall; it prevented shock-related increase in alcohol consumption only in iP rats, suggesting genotype-dependent effects.
preclinical (rat model)
MDMA-AT shows promising outcomes in RCTs with high response/remission rates, but key limitations include blinding challenges, lack of active comparators, inadequate safety monitoring, and limited generalizability.
review
MDMA-AT was associated with reductions in PTSD symptom severity (SMD=-1.19) and dissociative symptoms (SMD=-0.37), but most studies had high risk of bias and overall certainty was low.
systematic review and meta-analysis Sample size: 298
MDMA increased spine density and spinogenesis in prefrontal cortex, accelerated representational drift, and strengthened infralimbic cortex correlation with freezing suppression, suggesting enhanced neuroplasticity underlying extinction learning.
preclinical (mouse model)
Repeated low-dose MDMA caused transient next-day anxiety-like behavior and reduced serotonin in nucleus accumbens, but no effect on anhedonia-like behavior; effects resolved by day 15.
preclinical (rat model)
MDMA and ketamine IV have the greatest support for efficacy in PTSD, but caution is needed due to treatment expectancy effects and potential for inadequate blinding.
systematic review
Psychedelic research in pediatric populations is emerging but requires caution due to developmental vulnerabilities; MDMA is not yet studied in adolescents.
review
Integration of MDMA with psychoanalysis appeared to facilitate access to unconscious material and therapeutic progress in a single OCD case, but efficacy requires systematic investigation.
case report Sample size: 1
The paper argues that embedding MDMA in structured cognitive-behavioral protocols may blunt its transformative effects and that the patient-directed model should be preserved and refined.
theoretical/perspective
Commentary on critical considerations for clinical translation of MDMA-assisted psychotherapy in major depression.
commentary
Stereoselective analysis of MDMA and MDA in oral fluid showed faster elimination of S-(+)-MDMA (half-life 3.3h) vs R-(-)-MDMA (4.8h), enabling estimation of time since ingestion.
observational (pharmacokinetic) Sample size: 161
Amino acid prodrugs of MDMA (MDMA-Trp, MDMA-Lys, MDMA-Gly) are cleaved to MDMA in zebrafish, liver S9, and human urine, with unique biomarkers for MDMA-Trp; no cleavage in blood.
preclinical (zebrafish, human liver S9, human urine)
Corrigendum to a previous study on Withania somnifera influencing MDMA-induced effects in mice; no new findings.
corrigendum
Correction to a study on next-generation MDMA analogue SDMA; all results and conclusions remain accurate.
correction
Experts agreed that 150 mg free-base MDMA is a reasonable threshold for issuing public drug alerts, though thresholds cannot account for evolving trends.
qualitative Sample size: 15
History with eutylone attenuated eutylone-induced taste avoidance but did not affect MDMA- or cocaine-induced avoidance; eutylone history increased cocaine place preference but not MDMA's.
preclinical (rat model)
Points of agreement
- MDMA-assisted therapy reduces PTSD symptoms with moderate-to-large effect sizes in meta-analyses of RCTs.
- MDMA enhances fear extinction and prefrontal neuroplasticity in animal models.
- Methodological limitations (blinding, expectancy, high risk of bias) are consistently noted across human studies.
- MDMA's effects on alcohol consumption and anxiety are genotype- and sex-dependent in preclinical models.
Conflicts
- One meta-analysis (27849) reports Hedges' g = -0.71 for PTSD symptoms, while another (25094) reports SMD = -1.19, possibly due to different inclusion criteria or analytic methods.
- Preclinical studies show MDMA reduces stress-induced alcohol intake in iP rats but not Wistar rats (28514), and transient anxiety in rats (25152) contrasts with therapeutic anxiolytic effects in humans.
- The patient-directed model (25131) argues against structured protocols, while other reviews (25110) call for integration with established trauma-focused therapies.
Gaps
- No new large-scale, double-blind, active-comparator human trials published in this period.
- Long-term durability of MDMA-AT effects beyond short-term follow-up is not established.
- Safety and efficacy in adolescents and diverse populations remain unstudied.
- Mechanisms of action (e.g., neuroplasticity, fear extinction) are primarily from animal models; human neural evidence is lacking.
- Optimal dosing, number of sessions, and therapeutic model (structured vs. patient-directed) are not resolved.